|
26 Oct 2020 |
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
|
|
26 Oct 2020 |
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
|
|
23 Oct 2020 |
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
|
|
23 Oct 2020 |
Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy
|
|
23 Oct 2020 |
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
|
|
23 Oct 2020 |
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
|
|
22 Oct 2020 |
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
|
|
21 Oct 2020 |
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
|
|
21 Oct 2020 |
Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells
|
|
19 Oct 2020 |
OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference
|
|
19 Oct 2020 |
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
|
|
16 Oct 2020 |
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
|
|
16 Oct 2020 |
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
|
|
16 Oct 2020 |
Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
|
|
16 Oct 2020 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
16 Oct 2020 |
Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma
|
|
16 Oct 2020 |
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
|
|
16 Oct 2020 |
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
|
|
16 Oct 2020 |
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
|
|
16 Oct 2020 |
OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy
|
|
16 Oct 2020 |
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
|
|
14 Oct 2020 |
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
|
|
13 Oct 2020 |
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
|
|
13 Oct 2020 |
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
|
|
13 Oct 2020 |
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
|
